EARLY ACS TRIAL OF INTEGRILIN

Millennium Pharmaceuticals announced publication of the EARLY ACS trial design and rationale in the June 2005 issue of the American Heart Journal.

The EARLY ACS trial design incorporates new technologies and reflects current treatment patterns in patients with non-ST elevation acute coronary syndromes (nSTE ACS) in a "real-world" setting. nSTE ACS is the term applied to unstable angina and non-ST elevation myocardial infarction.

The trial is designed to provide evidence regarding the potential benefit of initiating Integrilin, a potent glycoprotein IIb-IIIa inhibitor, early after patients present with high-risk acute coronary syndromes versus delaying use until patients undergo coronary angiography. In addition, the trial will also explore the ability of biomarkers to identify high-risk patients who will receive the greatest benefit from an early aggressive approach.